Certolizumab Pegol
Certolizumab Pegol
Immunoglobulin, anti-(human tumor necrosis factor alpha) Fab' fragment (human-mouse monoclonal CDP870 heavy chain, disulfide bonded with human-mouse monoclonal CDP870 light chain), pegylated at Cys-227 on the heavy chain
Stoffgruppe
Immunsuppressivum (TNF-alpha-Inhibitor)
Halbwertszeit
ca. 14 Tage